Executive Summary
A single-center two-era comparison shows the 30-day death-or-stroke rate for TAVR collapsed from 10% to 1% while SAVR outcomes stayed excellent in a markedly younger surgical cohort — a redistribution, not a replacement, that mirrors what the ESC 2025 guideline codified by lowering the TAVI-preferred threshold to age 70. Persistent moderate-or-severe MR after TAVR predicts worse survival, with sex and flow-gradient phenotype determining who regresses: only 52.9% of patients reached mild-or-less MR, and in the low-flow low-gradient subgroup residual severe MR drove excess mortality. A meta-analysis of 1,522 cancer patients undergoing M-TEER shows 72% higher long-term mortality despite equivalent procedural success — patient selection, not the clip, is the story. Edwards booked a $39 million securities class action settlement, tightening scrutiny on how TAVR growth stories are marketed to investors.
- Two-era institutional TAVR data: 30-day death-or-stroke fell from 10% to 1%, PVL ≥mild from 27% to 3%, LOS from 6 to 1 day (Nickles et al.).
- Post-TAVR residual MR is worse in women and LFLG AS; residual severe MR drove excess mortality only in the LFLG subgroup (JACC Advances).
- M-TEER in cancer patients: HR 1.72 for long-term mortality across 8 observational studies; matched cohorts blunt the signal (GeroScience).
- AI-ECG on a portable 1-lead device detected severe SHD with AUROC 0.872, cutting NNT from 19.7 to 6.9 (ACCESS-SHD, medRxiv preprint).
- CMS expanded coverage across heart failure technology categories in the latest ACCESS update (Cardiovascular Business).
What to watch: Edwards' October 29 earnings, where TAVR volume guidance and the M3 mitral program will be dissected against the SAPIEN M3 EFS completion posted this week.
Aortic Valve (TAVR/TAVI)
The single-center two-era analysis published in Medical Sciences is the day's most instructive TAVR data — and its most misread. Comparing 100 consecutive isolated TAVRs from 2012 with 100 from 2024, the 30-day composite of death or stroke fell from 10% to 1%, PVL ≥mild dropped from 27% to 3%, and hospital stay collapsed from 6 to 1 day (unadjusted, single-center, N=100 per era). Over the same window, SAVR outcomes stayed excellent — composite 2% to 0% — but the surgical cohort became younger (74 to 64 years), and isolated first-time SAVR took 18.9 months to accrue versus 5.7 months a decade ago. This is the redistribution the ESC 2025 guideline codified when it moved the TAVI-preferred threshold to age ≥70 with suitable transfemoral anatomy while keeping SAVR Class I for patients under 70 with low surgical risk (STS + EuroSCORE II <4%). ACC/AHA 2020 places the shared-decision zone at 65–80, so US practice reads this data through a different lens — one that still favors SAVR for patients under 65 on durability grounds that 10-year RCT data have not yet resolved.
Post-TAVR MR persistence in LFLG AS and women is the durability caveat that remains under-reported: 47% of patients did not regress to mild MR, and in the LFLG AS subgroup residual severe MR drove mortality. ESC 2025 and ACC/AHA 2020 both recognize LFLG AS as a distinct phenotype requiring confirmatory CT calcium scoring (≥2,000 AU in men, ≥1,200 AU in women); neither guideline adequately addresses post-TAVR MR surveillance intervals or thresholds for reintervention. A very-late Stanford A dissection four years after Evolut R implantation is a reminder that lifetime aortic surveillance in self-expanding TAVR recipients is unresolved — ESC 2025's lifetime management framework addresses redo-valve planning but not aortic complications at this time horizon. Finally, TAVI-TEC, an AI-CTA planning tool, achieved 77.1% valve-size accuracy for SAPIEN 3 Ultra in a feasibility cohort — most errors landed on adjacent sizes, and the tool has not been validated beyond a single valve platform or center.
Mitral Valve (MitraClip, PASCAL, TMVR)
M-TEER in cancer patients works procedurally but not prognostically. The GeroScience meta-analysis pooled 8 observational studies (1,522 cancer patients, 4,716 controls) and found 72% higher long-term all-cause mortality (HR 1.72, 95% CI 1.03–2.90, I²=74.8%) despite identical 30-day mortality and procedural success rates. Matched cohorts attenuate the signal to non-significance — the excess mortality is driven by frailty and treatment-related comorbidity, not the clip itself. The caveat is methodological: observational pooling with high heterogeneity (I²=74.8%) across 8 non-randomized studies cannot establish causation, and matched analyses are limited by unmeasured confounding. ESC 2025 upgraded TEER for ventricular secondary MR to Class I, LOE A on the strength of COAPT and RESHAPE-HF2; ACC/AHA 2020 remains at Class IIa. Patient selection is where that gap gets litigated — and the cancer population sits at the edge of the COAPT eligibility criteria the ESC codified.
A JACC Case Reports piece describes parallel septal balloon occlusion to manage acute right-to-left shunt during PASCAL deployment — a technical bail-out worth cataloguing. A JACC Advances editorial argues that very severe LV dysfunction is not an absolute contraindication to M-TEER, directly pressuring the COAPT LVEF floor of 20%; the argument is hypothesis-generating, not data-driven, and the COAPT lower-bound exclusion exists precisely because the signal below that threshold is unknown.
Tricuspid Valve (TriClip, TTVR)
No new tricuspid-specific trial data today. The reference frame for the field is the ESC 2025 Class IIa, LOE A recommendation for transcatheter TV treatment in high-risk symptomatic severe TR without severe RV dysfunction — a category ACC/AHA 2020 did not address because TRILUMINATE, Tri.Fr, and TRISCEND II had not yet reported. The next inflection points are TRISCEND II two-year outcomes and any label expansion for the EVOQUE system beyond its current approved criteria.
Surgical vs. Transcatheter Comparisons
The two-era single-center comparison is not a head-to-head trial — the authors frame it correctly as unadjusted within-modality change against a shifting risk pool. The read-across is real nonetheless: SAVR is now the operation for younger, more complex, and bicuspid anatomy patients; TAVR is absorbing the older, isolated-AS population. ESC 2025 built its framework explicitly around this division. ACC/AHA 2020's 65-year SAVR floor looks conservative against DEDICATE and 5-year PARTNER 3 and Evolut Low Risk data, but the 10-year structural valve deterioration story — where TAVI's exposure is greatest — has not been settled by any RCT. Until it is, SAVR retains the durability argument for patients under 65–70 with life expectancy that exceeds the data horizon.
Preprint Highlights
[NOTABLE] The ACCESS-SHD study (medRxiv preprint, N=597) tested an AI-enhanced 1-lead KardiaMobile 6L for detecting severe SHD in outpatients pre-echo. AUROC 0.872, sensitivity 86.7%, NPV 99.0%, and a categorical NRI of 24.3% over the device's native rhythm interpretation, cutting NNT from 19.7 to 6.9. Prevalence was 5.1%, so PPV sits at 14.4% — this is a triage tool, not a diagnostic. Limitations are significant: single algorithm, single device, single referral population, no external validation cohort. The direction of travel — portable AI-ECG feeding structural heart clinics — is clear, but the screening pathway change requires prospective multicenter confirmation before implementation.
Device & Technology
Two AI and computational tools cross the desk. TAVI-TEC automated CTA planning for SAPIEN 3 Ultra in 2–6 minutes with 77.1% valve-size accuracy — most misses landed on adjacent sizes. Feasibility only; multicenter external validation and expansion beyond a single valve platform are prerequisites for clinical adoption. A CFD proof-of-concept study modeled catheter-induced hemodynamic disturbance during transfemoral TAVI delivery, quantifying pressure drops and wall shear stress at the access-side iliac. The findings are mechanistically interesting for procedural risk stratification but are not clinically actionable from a single computational model. Apollo Hospitals reported a zero-contrast TAVR in a kidney transplant recipient — case-level, but a growing technical niche as end-stage renal patients with severe AS increasingly present for intervention.
Regulatory & Policy
CMS expanded coverage for heart failure technologies in the latest ACCESS update. The structural heart read-through is direct: broader HF coverage supports the pre-referral population feeding into TEER and TTVR, given that patients meeting COAPT criteria — NYHA ≥II, LVEF 20–50%, at least one HF hospitalization in the prior year — typically arrive through HF clinic pathways.
Industry & Market
The semaglutide cardiovascular signal may compress the frailty gradient that has justified TAVI over SAVR in borderline patients — mechanism remains unclear, but GLP-1 uptake in the AS population is a variable the field has not yet priced into procedural volume forecasts. A market forecast piece from IndexBox pins TAVR growth through 2035 on low-risk expansion — consistent with ESC 2025 but running ahead of ACC/AHA 2020, which has not yet incorporated DEDICATE or EARLY TAVR into its framework. Edwards named a GE HealthCare veteran to lead a new digital engineering group — continued investment in the imaging and AI-planning stack that tools like TAVI-TEC represent.
Financial Analysis
Edwards booked a $39 million securities class action settlement, with shares softening on the news. The underlying question — whether TAVR growth was oversold to the market in the disclosed period — is the commercial mirror of the guideline question about whether TAVI's low-risk expansion has outpaced durability data. The SAPIEN M3 EFS completion posted this week puts Edwards' next mitral chapter on the runway ahead of October 29 earnings. Boston Scientific's 36% six-month drawdown remains the structural anomaly in the group — a valuation reset not yet matched by fundamental deterioration in the WATCHMAN or FARAPULSE franchises, both of which touch structural heart tangentially.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $85.82, +0.10% on the day; +3.80% over six months
- Market cap $49.4B; trailing P/E 51.08, forward P/E 25.41; beta 0.85
- 52-week range $72.30–$96.29
- Analyst consensus target $100.96 (range $84–$110, 26 analysts); Buy
- Next earnings 2026-10-29; EPS est $0.74, revenue est $1.68B
The $39M class action settlement and a weaker trading session set an uneasy tone into October 29 earnings. TAVR volume commentary and any read on M3 EFS transition to pivotal will move the stock more than the headline print.
Medtronic (MDT)
- Close $87.93, -0.66% on the day; +1.77% over six months
- Market cap $112.5B; trailing P/E 21.66, forward P/E 13.73; beta 0.57
- 52-week range $73.31–$106.33
- Analyst consensus target $104.83 (range $85–$121, 24 analysts); Buy
- Next earnings 2026-11-17; EPS est $1.33, revenue est $9.48B
Evolut continues to hold share in the self-expanding TAVR segment. The very-late Stanford A dissection case published today is a reminder that lifetime aortic surveillance in Evolut recipients is unresolved territory — ESC 2025's lifetime management framework covers redo-valve planning but does not specify surveillance protocols for aortic complications at the 4-year horizon.
Abbott (ABT)
- Close $100.53, -0.53% on the day; -2.81% over six months
- Market cap $175.1B; trailing P/E 32.53, forward P/E 16.57; beta 0.59
- 52-week range $81.97–$135.45
- Analyst consensus target $120.26 (range $103–$135, 25 analysts); Buy
- Next earnings 2026-10-14; EPS est $1.42, revenue est $12.99B
MitraClip and TriClip sit inside a structural heart franchise that benefits directly from ESC 2025's Class I upgrade for TEER in ventricular secondary MR. The cancer M-TEER meta-analysis published today will pressure selection criteria more than total volume — the relevant question is whether cancer patients were excluded from the COAPT and RESHAPE-HF2 enrollment criteria that underpinned the ESC upgrade.
Boston Scientific (BSX)
- Close $44.38, -0.67% on the day; -36.40% over six months
- Market cap $64.3B; trailing P/E 17.97, forward P/E 13.00; beta 0.57
- 52-week range $42.20–$105.65
- Analyst consensus target $61.00 (range $44–$94, 29 analysts); Buy
- Next earnings 2026-10-28; EPS est $0.77, revenue est $5.16B
The six-month drawdown is at odds with analyst targets 37% above current levels. Structural heart exposure via ACURATE remains a secondary story; watch the October 28 print for franchise segmentation detail.
Anteris Technologies (AVR.AX)
- Close A$10.69, -0.37% on the day; +32.80% over six months
- Market cap ~A$1.0B; forward P/E -4.93
- 52-week range A$5.20–A$15.47
- Single-analyst target A$13.00
The DurAVR balloon-expandable single-piece design remains the differentiated pre-commercial TAVR story; the run-up reflects pivotal trial optimism, not revenue.
Market outlook: Structural heart names are trading on two clocks — a near-term one tied to Q3/Q4 earnings and volume guidance, and a longer one tied to whether ACC/AHA closes the age-threshold gap with ESC 2025 in its next update. Edwards' October 29 and Abbott's October 14 prints will set the tone.
Clinical Trial Updates
Aortic
- NCT07843004 — Capitalizing on AI to CapTure Undiagnosed Structural Heart Disease. RECRUITING. Enrollment 4,000. Sponsor: Pierre Elias. EHR alert intervention; aligns with the ACCESS-SHD preprint direction of travel.
Mitral Replacement
- NCT03230747 — SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for Mitral Regurgitation. COMPLETED. Enrollment 72. Sponsor: Edwards Lifesciences. Status change worth flagging — clears the path for pivotal design commentary at Edwards' next earnings.
Landmark trials that continue to frame today's data: EARLY TAVR, PARTNER 3, Evolut Low Risk, DEDICATE (AS); COAPT, RESHAPE-HF2, MITRA-FR, REPAIR-MR (MR); TRILUMINATE, Tri.Fr, TRISCEND II (TR).
Social & Conference Highlights
No congress today. TCT 2026 abstracts remain the next inflection for real-world TAVR durability and transcatheter tricuspid data. The DEDICATE two-year read and any EARLY TAVR subgroup analyses will be the sessions to watch.
Forward look: Edwards' October 29 print — with the M3 EFS just closed and a class action settlement in the rearview — will tell us whether the TAVR growth story is being priced on volume or on the next mitral chapter.